biote Corp. (NASDAQ:BTMD – Get Rating) CFO Samar Jagat Kamdar acquired 13,000 shares of biote stock in a transaction dated Monday, January 9th. The shares were bought at an average price of $3.00 per share, for a total transaction of $39,000.00. Following the transaction, the chief financial officer now owns 13,000 shares of the company's stock, valued at $39,000. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
biote Stock Up 11.9 %
Shares of NASDAQ BTMD traded up $0.40 during midday trading on Tuesday, reaching $3.75. 142,380 shares of the stock traded hands, compared to its average volume of 327,212. The company's 50 day moving average is $3.96 and its 200 day moving average is $4.11. biote Corp. has a one year low of $2.00 and a one year high of $10.52.
Get biote alerts:biote (NASDAQ:BTMD – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.14 by ($0.23). The business had revenue of $41.97 million for the quarter, compared to analyst estimates of $41.86 million. As a group, equities analysts predict that biote Corp. will post 0.78 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, Truist Financial assumed coverage on shares of biote in a research note on Tuesday, September 27th. They set a "buy" rating and a $10.00 target price for the company.Institutional Investors Weigh In On biote
Large investors have recently added to or reduced their stakes in the stock. Pitti Group Wealth Management LLC purchased a new position in shares of biote in the 3rd quarter worth approximately $105,000. Prelude Capital Management LLC bought a new stake in biote in the second quarter worth $250,000. Cowen AND Company LLC purchased a new position in biote during the second quarter worth $49,000. Millennium Management LLC bought a new position in biote during the second quarter valued at $445,000. Finally, Creative Planning purchased a new stake in shares of biote in the second quarter valued at $44,000. 3.81% of the stock is owned by institutional investors.
About biote
(Get Rating)
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements.
See Also
- Get a free copy of the StockNews.com research report on biote (BTMD)
- Can Lockheed Martin Corporation Hit Another All-Time High in Q1?
- Marathon Digital Holdings, Inc: Slow And Steady Wins The Race
- The WD-40 Company Is Ready To Rebound, But Will It?
- Skechers Not Nike Is The Sneaker Stock to Own for 2023
- Can The Rally In e.l.f. Beauty Stock Continue?
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.